Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07629726 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms
A Phase 1 study, sponsored by Kyowa Kirin Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT07629726 is a Phase 1 study that is actively recruiting participants, run by Kyowa Kirin Co.. The registered enrollment target is 72 participants.
The verdict
NCT07629726, a Phase 1 study, is actively recruiting participants, sponsored by Kyowa Kirin Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given to people. The purpose of this Study is to find out more information about KK2430, whether it is safe in humans, how the body processes it, and if it works for treating your condition.
Interventions
- DRUG KK2430
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07629726
The ClinicalTrials.gov registry entry for NCT07629726 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin Co., which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KK2430 is the first listed.
NCT07629726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07629726 about?
NCT07629726 is a clinical study titled "A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms". KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given ...
What is the current status of trial NCT07629726?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2026-06. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07629726?
The interventions under investigation include: KK2430 (DRUG).
Who is sponsoring clinical trial NCT07629726?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.